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A New Aspergillus fumigatus Resistance Mechanism Conferring
In Vitro Cross-Resistance to Azole Antifungals Involves
a Combination of cyp51A Alterations
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Fourteen Aspergillus fumigatus clinical isolates that exhibited a pattern of reduced susceptibility to
triazole drugs were analyzed. The sequences of the cyp51A gene from all isolates showed the presence of
a point mutation at t364a, which led to the substitution of leucine 98 for histidine (L98H), together with
the presence of two copies of a 34-bp sequence in tandem in the promoter of the cyp51A gene. Quantitative
expression analysis (real-time PCR) showed up to an eightfold increase in the level of expression of the
cyp51A gene compared to that by the susceptible strain. Three PCR fragments of one azole-resistant strain
(strain CM2627) that included the promoter with the tandem repeat and part of cyp51A with the t364a
mutation or PCR fragments with only one of the modifications were used to replace the cyp51A gene of an
azole drug-susceptible A. fumigatus wild-type strain (strain CM237). Only transformants which had
incorporated the tandem repeat in the promoter of the cyp51A gene and the L98H amino acid substitution
exhibited similarly reduced patterns of susceptibility to all triazole agents and similarly increased levels
of cyp51A expression, confirming that the combination of both alterations was responsible for the azole-
resistant phenotype.
Infections with Aspergillus fumigatus, one of the most prev-
alent airborne fungal pathogens causing invasive aspergillosis
worldwide, result in high rates of mortality and morbidity in
immunocompromised hosts (20, 21). A. fumigatus is intrinsi-
cally resistant to fluconazole, but other triazole drugs like itra-
conazole and voriconazole are active both in vitro and in vivo
against this species. Also, the new triazoles, such as posacon-
azole and ravuconazole, have been shown to have good in vitro
activities against this species (5, 7, 17, 37, 45). In many centers
voriconazole has become a common choice for the primary
therapy of invasive aspergillosis, as the drug has been shown to
have superior efficacy compared with those of other licensed
antifungal therapies, most notably, amphotericin B (19). Nev-
ertheless, more than half of patients still fail to respond to
antifungal therapy. Although this is mainly due to factors re-
lated to the host, the resistance of Aspergillus to triazole drugs
might play a role (22, 47). Indeed, a number of A. fumigatus
isolates with in vitro itraconazole resistance have been de-
scribed (3, 8, 13, 15, 24, 31), and strains that show high MICs
against the new triazole agents are being reported (29, 31, 37).
We recently observed primary and breakthrough cases of in-
vasive aspergillosis due to A. fumigatus isolates with a pheno-
type characterized by high MICs of itraconazole, voriconazole,
and ravuconazole and elevated MICs of posaconazole (51).
There was no apparent epidemiological link between the cases.
In filamentous fungi, azole drugs inhibit ergosterol biosyn-
thesis by targeting the enzyme 14--sterol demethylase
(Cyp51). So far, the prevalence of mechanisms for azole drug
resistance in A. fumigatus seems to be very different from that
in Candida spp. In A. fumigatus, there are two different but
related Cyp51 proteins, and these are encoded by cyp51A and
cyp51B (28). Targeted disruption of the cyp51A gene in differ-
ent itraconazole-resistant A. fumigatus strains resulted in
strains with similar patterns of decreased susceptibility to azole
drugs, confirming that Cyp51A is the target of these antifungal
agents (30). In itraconazole-resistant A. fumigatus strains, two
molecular mechanisms of resistance to azole drugs have been
described: first, azole drug resistance in A. fumigatus seems to
be mostly related to point mutations in Cyp51A (2, 15, 25, 29,
32); and second, reduced intracellular accumulation, due to
either increased expression of efflux pumps (13, 46) or reduced
penetration of the drug (24), have also been proposed.
Regarding the modification of A. fumigatus Cyp51, specific
mutations in cyp51A have been associated with two different
susceptibility profiles: (i) cross-resistance to itraconazole and
posaconazole has been associated with amino acid substitu-
tions at glycine 54 (G54) (15, 25, 32); and (ii) a pattern of
itraconazole resistance, characterized by different patterns of
elevated MICs for azole drugs, has been linked to different
amino acid substitutions at methionine 220 (M220) (2, 29).
Here we describe the analysis of a new molecular mecha-
nism responsible for a phenotype of A. fumigatus cross-resis-
tance to azole drugs. We have determined that a base change
causing an amino acid substitution in Cyp51A (L98H) in com-
bination with the duplication in tandem of a 34-bp sequence in
the cyp51A promoter, which is responsible for the increased
* Corresponding author. Mailing address: Servicio de Micologia,
Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Car-
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level of cyp51A gene expression, accounted for the resistant
phenotype.
(Part of this study was presented at the 45th Interscience
Conference on Antimicrobial Agents and Chemotherapy,
Washington, DC, December 2005.)
MATERIALS AND METHODS
Fungal strains and media. The fungal strains used in the study included (i) A.
fumigatus strain CM237 (CM refers to the fungal collection of the Mycology
Reference Laboratory at the Centro Nacional de Microbiologia, ISCIII) was
used to describe the cyp51A and cyp51B gene sequences and was also the control
strain (28); (ii) A. fumigatus strain akuBKU80 (10) was used as the recipient strain
in some experiments of fungal transformation; and (iii) 14 clinical A. fumigatus
strains were isolated from 10 patients (1 from Spain and 13 from the collection
of the Department of Medical Microbiology, Radboud University Nijmegen
Medical Center, Nijmegen, The Netherlands) (Table 1). The fungi were grown at
37°C in potato dextrose agar (Oxoid, Madrid, Spain), GYEP broth (2% glucose,
0.3% yeast extract, 1% peptone), and minimal medium (38). Conidial stocks
were preserved in sterile distilled water (15).
Antifungal susceptibility testing: MICs. Broth microdilution susceptibility
testing was performed as described in CLSI (formerly NCCLS) document
M38-A (33), with modifications (6, 35, 40). Itraconazole (Janssen Pharmaceutical
S.A., Madrid, Spain), voriconazole (Pfizer, S.A., Madrid, Spain), ravuconazole
(Bristol-Myers Squibb, Madrid, Spain), posaconazole (Schering Plough, Madrid,
Spain), and amphotericin B (Sigma, Madrid, Spain) were tested. Susceptibility
tests were performed at least three times with each strain on different days.
Aspergillus flavus ATCC 204304 and A. fumigatus ATCC 204305 were used as
quality control strains for susceptibility testing.
PCR amplification and sequence analysis of cyp51A and cyp51B genes.
Conidia from each strain were inoculated in 3 ml GYEP broth and grown
overnight at 37°C. Mycelial mats were recovered and subjected to a DNA ex-
traction protocol (28). The full coding sequences of cyp51A and cyp51B were
amplified by PCR and both strands were sequenced, as described previously (15).
To rule out the possibility that any sequence changes identified were due to
PCR-induced errors, each isolate was independently fully analyzed twice. The
nucleotide sequences of the cyp51A and cyp51B genes in strains CM237 and
akuBKU80 are identical.
Aspergillus fumigatus transformations. Three linear DNA fragments were used
throughout this work for azole-susceptible A. fumigatus (CM237 and akuBKU80)
strain transformations: (i) a fragment containing the coding sequence of the
cyp51A gene with a single nucleotide change (t364a) that substitutes leucine for
histidine (named the L98H fragment), (ii) a fragment that includes the cyp51A
promoter sequence of the gene with the 34-bp tandem repeat (named the TR
fragment), and (iii) a fragment containing the coding sequence of cyp51A gene
with a t364a change that results in the L98H substitution in combination with the
34-bp TR in the cyp51A promoter (named the TRL98H fragment) (Fig. 1).
Linear fragments were obtained by PCR amplification of cyp51A by using
genomic DNAs from A. fumigatus strain CM2627 and the following primer sets:
(i) primer set P450A1-P450A2, (ii) primer set A7-A5, and (iii) primer set A7-A2
(28). First, the conidia of azole-susceptible wild-type strain CM237 were used as
the recipients for transformation by electroporation by separately using each of
the PCR-amplified linear fragments of cyp51A.
Electroporation was then carried out by a protocol previously described for
Aspergillus nidulans (41) and subsequently adapted for A. fumigatus (52). Trans-
formants were selected on medium containing itraconazole (8 g/ml or 1 g/ml),
as described previously (15). Itraconazole-resistant transformants appeared after
2 to 7 days of incubation.
Using these conditions, we were unable to recover any transformant carrying
the L98H mutation at cyp51A. A different azole-susceptible A. fumigatus strain
(akuBKU80), which has an increased frequency of homologous recombination
(10), was used as the recipient strain for electroporation by using the PCR-
amplified linear fragments of cyp51A that included the TR or the L98H fragment
independently. Transformants were selected on medium containing itraconazole
(0.5 to 1.0 g/ml), as described above. The transformants were labeled with
“TR,” “L98H,” or “TRL98H,” followed by a number, depending on the DNA
fragment used for the electroporation, and preceded by the identification num-
ber of the recipient strain (CM237 or akuBKU80).
RNA isolation and reverse transcription-PCR. Total RNA was extracted from
the A. fumigatus azole-susceptible strains (strains CM237 and akuBKU80), two of
the clinical isolates (isolates CM2627 and CM3275), the transformants obtained
from strain CM237 (transformants CM237-TRL98H1 and CM237-TR7), and the
transformants obtained from strain akuBKU80 (transformants akuBKU80-TR2,
akuBKU80-TR3, akuBKU80-L98H1, and akuBKU80-L98H3). The reverse tran-
scription reactions were performed as described before (1). First, we evaluated
the cyp51A transcription level differences between azole-susceptible A. fumigatus
TABLE 1. Clinical data for patients infected or colonized with azole-resistant A. fumigatus, genotypes, and ranges of MICs of different
antifungals for the isolatesa
Sex (age) Underlying disease
Azole exposure prior to
aspergillosis diagnosis
(time)
A. fumigatus isolate Date of isolation(day-mo-yr) Genotype
MIC (g/ml)
AMB ITC VRC RVC PSC
F Unknown Unknown M03/669 - CM2627 21-10-2003 A 0.25 8 4–8 4–8 0.5
M (15) X-linked CGD ITC (6 yr) V13/02 - CM3271 04-04-2002 B 0.25 8 2 8 1
V13/03 - CM3272 05-04-2002 B 0.25 8 2 8 1
M (73) No No V27/28 - CM3273 03-12-2003 C 0.25 8 4 4–8 1
F (77) AML VRC (77 days) V28/78 - CM3275 02-03-2004 D 0.25 8 4 8 0.5–1
M (16) Hyper-IgE syndrome VRC (2 yr) V34/75 - CM3276 19-11-2004 E 0.25 8 4 4 0.5
V34/76 - CM3277 E 0.25 8 2–4 4 0.5-1
V34/77 - CM3278 E 0.25 8 2 4 0.5
V34/78 - CM3279 E 0.25 8 2 4 0.5
F (76) Pulmonary fibrosis No V41/26 - CM3820 26-06-2005 F 0.25 8 4–8 4–8 0.5–1
M (31) CGD ITC (10 yr) V45/07 - CM3819 01-11-2005 G 0.25 8 8 8 1
F (68) AML No V48/27 - CM3936 14-02-2006 H 0.25 8 4 8 4
F (62) COPD No V49/09 - CM4023 05-04-2006 I 0.25 8 4 8 4
M (45) AML ITC (2 yr) V49/77 - CM4050 11-05-2006 J 0.25 8 4 4–8 1
a IgE, immunoglobulin E; CGD, chronic granulomatous disease; AML, acute myeloid leukemia; COPD, chronic obstructive pulmonary disease; AMB, amphotericin
B; ITC, itraconazole; VRC, voriconazole; RVC, ravuconazole; PSC, posaconazole; F, female; M, male.
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CM237 and the akuBKU80 strains used for the transformation experiments. Then,
we evaluated the cyp51A transcription level differences between the transfor-
mants and their parental strains. For transcription level determination, a real-
time PCR assay was performed as follows: the levels of expression of the target
gene (cyp51A) were quantified for each strain by comparison with their respec-
tive control or parental strain and by use of the A. fumigatus -tubulin house-
keeping gene (tub1) as a reference for gene expression. The primer set A6-
CypA2 (28) was used to amplify the cDNA from the cyp51A gene. The primer set
Tub5 (5-TGACCCAGCAGATGTT-3) and Tub6 (5-GTTGTTGGGAATCC
ACTC-3) was used for the amplification of a fragment of the A. fumigatus
-tubulin gene (GenBank accession number AY048754). Real-time PCRs were
set up with the FastStart DNA Master SYBR green (Roche Diagnostic). Each
assay was repeated in duplicate and with RNA from at least two different RNA
extractions. Each experiment included standard curves for the target gene
(cyp51A) and for the reference gene. The PCR efficiencies of -tubulin and
cyp51A cDNA amplification were calculated from the slopes of the curves given
by LightCycler software (Roche Diagnostic), and the efficiency values were used
to validate each experiment and also for relative quantification by the method of
Pfaffl (36).
Genotyping of Aspergillus isolates. The A. fumigatus isolates were genotyped by
using a panel of short tandem repeats (STRs). Two sets of three STRs (M3 and
M4) consisting of tri- and tetranucleotide motifs were used in separate multicolor
multiplex PCRs to analyze both A. fumigatus azole-resistant and azole-suscepti-
ble (control) isolates. For each of the multiplex PCRs with STRs M3 and M4, the
forward primers were labeled with carboxyfluorescein, hexachlorofluorescein, or
tetrachlorofluorescein at the 5 end. The primer sequences were used exactly as
described previously (14). Each PCR mixture contained 1 M all amplification
primers, 3.0 mM MgCl2, 0.2 mM deoxynucleoside triphosphates, 1 U of FastStart
Taq DNA polymerase, and 1 ng of genomic DNA in 1 reaction buffer. The
thermoprofile was 10 min of denaturation at 95°C, followed by 30 cycles of 30 s
of denaturation at 95°C, 30 s of annealing at 60°C, and 1 min of extension at
72°C. Before the reaction mixtures were cooled to room temperature, an addi-
tional incubation for 10 min at 72°C was performed. The fragments obtained
were combined with the ET400-R size standard (GE Healthcare, Roosendaal,
The Netherlands) and analyzed on a MegaBACE 500 automated DNA platform
(GE Healthcare).
Data analysis. The significance of the differences in MICs was determined by
Student’s t test after logarithmic conversion of the values (unpaired, unequal
variance). For statistical evaluation of the crossing point and relative expression
variations, the data were analyzed by analysis of variance for significant differ-
ences. Statistical analysis was done with the SPSS package (version 14.0; SPSS
S.L., Madrid, Spain). A P value of 0.01 was considered significant.
RESULTS
Antifungal susceptibility testing: MICs. All 14 strains were
obtained from patients under different clinical conditions, and
only half of the patients had a history of exposure to azole
drugs (Table 1). To investigate whether these mutations orig-
inated from a clonal Aspergillus strain, the different isolates
were genotyped by using a panel of microsatellites or STRs.
STR analyses yield highly reproducible, exact typing results.
Each multiplex reaction amplified three trinucleotide repeats.
For each different STR, between 6 and 85 alleles were found.
The isolates from all patients showed unique genetic profiles,
indicating no genetic relatedness between the different A. fu-
migatus isolates (Table 1). The 14 strains exhibited a common
pattern of reduced susceptibility to all four triazoles tested with
various MICs, depending on the antifungal drugs, with
posaconazole being the most active compound in vitro. The
MICs for amphotericin B showed no variations between any
strains (Table 1).
PCR amplification and sequence analysis of cyp51A and
cyp51B genes. Sequence analysis of cyp51A showed the same
t364a point mutation in all strains, resulting in an amino acid
substitution with histidine (L98H) at the leucine 98 codon.
Two isolates (both from the same patient) had two extra base
changes: these were t960a and t1554a, which were responsible
for amino acid changes of serine for threonine at codon 297
(S297T) and phenylalanine for isoleucine at codon 495
(F495I), respectively (Table 2). All strains also contained three
different point mutations in the cyp51B gene that were not
conserved across the 14 isolates, although all of them were
silent (Table 2). The sequence alignments of the region en-
compassing L98 revealed that this amino acid residue is not
totally conserved in all yeasts and molds. However, the fact
that all azole-resistant strains carried the same mutation
FIG. 1. Diagram of the A. fumigatus cyp51A gene and promoter showing the locations of the gene modifications and the primers used for PCR
amplification of the different cyp51A gene fragments: (A) Wild-type strain CM237; (B) azole-resistant strain CM2627. The primer sets were as
follows: (i) primer set A7-A2, which contains the TR and the t364a base change; (ii) primer set A7-A2, which contains only the 34-bp TR; and
(iii) primer set P450A1-P450A2, which amplifies the full cyp51A gene, including only the t364a base change (L98H).
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strongly suggested that the substitution was associated with
azole drug resistance. Moreover, all strains had a duplication
in tandem of a 34-bp sequence in the cyp51A promoter (5-G
AATCACGCGGTCCGGATGTGTGCTGAGCCGAAT3-)
located at positions 	288 and 	322 from the cyp51A start
codon. A BLAST database search based on the repeated se-
quence unit identified no striking similarities other than simi-
larity to the cyp51A promoter region of A. fumigatus deposited
in the GenBank database (accession numbers AF338659 and
AF222068).
The region encompassing the mutation and the repeat in the
promoter were sequenced in 25 A. fumigatus azole-susceptible
clinical strains, as well as in several A. fumigatus azole-resistant
strains with different known resistance mechanisms. None of
the strains had either the variation at codon L98 or the 34-bp
tandem duplication.
Levels of Cyp51A expression by A. fumigatus azole-resistant
strains. The levels of accumulation of cyp51A mRNA in two
azole-resistant clinical strains (strains CM2627 and CM3275)
in comparison with those in the A. fumigatus azole-susceptible
CM237 control strain were analyzed. The values presented in
Table 3 are the differences in the levels of transcription of
cyp51A between the azole-resistant strains and azole-suscepti-
ble strain CM237 normalized to the levels of transcription of
the reference -tubulin gene for each strain included in the
assay.
Replacement of wild-type cyp51A gene with different gene
modifications. Therefore, the cyp51A gene fragments which
had been amplified from strain CM2627 by PCR and which
carried the different cyp51A modifications were electroporated
into wild-type (azole-susceptible) A. fumigatus strain CM237.
The different PCR fragments (L98H, TR, and TRL98H) were
individually electroporated into wild-type A. fumigatus strain
CM237 (Fig. 1). When itraconazole (8 g/ml) was used for
selection, mutants (n 
 15) were obtained only when TRL98H
PCR fragment was used for transformation (strains CM237-
TRL98H1 to CM237-TRL98H15). However, when 1 g/ml of
itraconazole was used as the selective concentration, only one
mutant (strain CM237-TR7) arose when the TR fragment ob-
tained by PCR was used for transformation. On the other
hand, after several experiments with the L98H fragment and
itraconazole at concentrations of 1 g/ml and 8 g/ml, we were
unable to obtain any mutant showing only the t364a base
change. Therefore, a different azole-susceptible A. fumigatus
strain (strain akuBKU80) was used as the recipient for electro-
poration with the linear fragments obtained by PCR which
included only one of the cyp51A modifications (the TR frag-
ment or the L98H fragment). Transformants were selected on
medium containing itraconazole (0.5 to 1.0 g/ml). By using
this strain, two mutants (strains akuBKU80-TR2 and akuBKU80-
TABLE 2. Nucleotide and amino acid substitutions in cyp51A and cyp51B genes from A. fumigatus clinical isolates
Isolate TRpromoter
Nucleotide substitutiona
cyp51A cyp51B
Codon 54 Codon 98 Codon 220 Codon 297 Codon 495 Codon 35 Codon 394 Codon 464
CM237 (wild type) (	) GGG CTC ATG TCG TTT TCT CCT ATT
akuBKU80b (	) GGG CTC ATG TCG TTT TCT CCT ATT
M03/669 - CM2627 () GGG 364CAC ATG TCG TTT TCT 1285CCG ATT
V13/02 - CM3271 () GGG 364CAC ATG 960ACG 1554ATT TCT 1285CCG 1495ATA
V13/03 - CM3272 () GGG 364CAC ATG 960ACG 1554ATT TCT 1285CCG 1495ATA
V27/28 - CM3273 () GGG 364CAC ATG TCG TTT TCT 1285CCG ATT
V28/78 - CM3275 () GGG 364CAC ATG TCG TTT 105TCC 1285CCG ATT
V34/75 - CM3276 () GGG 364CAC ATG TCG TTT TCT 1285CCG ATT
V34/76 - CM3277 () GGG 364CAC ATG TCG TTT TCT 1285CCG ATT
V34/77 - CM3278 () GGG 364CAC ATG TCG TTT TCT 1285CCG ATT
V34/78 - CM3279 () GGG 364CAC ATG TCG TTT TCT 1285CCG ATT
V41/26 - CM3820 () GGG 364CAC ATG TCG TTT 105TCC 1285CCG ATT
V45/07 - CM3819 () GGG 364CAC ATG TCG TTT TCT 1285CCG ATT
V48/27 - CM3936 () GGG 364CAC ATG TCG TTT 105TCC 1285CCG ATT
V49/09 - CM4023 () GGG 364CAC ATG TCG TTT TCT 1285CCG ATT
V49/77 - CM4050 () GGG 364CAC ATG TCG TTT TCT 1285CCG ATT
Amino acids (G54) (L98H) (M220) (S297T) (F495I) (S35S) (P394P) (I464I)
a Nucleotides are numbered from the translation start codon ATG of cyp51A and cyp51B. The numbers indicate the position at which a base change occurs (in
boldface).
b The akuBKU80 mutant strain (10) is a genetically modified A. fumigatus strain with a high frequency of homologous recombination.
TABLE 3. A. fumigatus cyp51A mRNA transcription levels of
different clinical and mutant strains with respect to
that for wild-type strain CM237
Strain
cyp51A mRNA
transcription levela
VC (%)b
Geometric
mean SD
CM2627 7.70 1.45 18.8
CM3275 8.05 1.25 15.5
CM237-L98HTR1 8.10 1.36 16.8
CM237-TR7 4.23 1.02 24.0
akuBKU80 recipient 1.48 0.10 6.9
akuBKU80-TR2 4.74 0.91 19.2
akuBKU80-TR3 8.23 1.96 23.8
akuBKU80-L98H1 0.65 0.15 22.9
akuBKU80-L98H3 1.32 0.14 17.8
a Geometric means for at least two different RNAs and six cDNAs. SD,
standard deviation.
b VC, coefficient of variation
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TR3) were obtained when the PCR-generated TR fragment
was used for transformation and five mutants (strains
akuBKU80-L98H1 to akuBKU80-L98H5) were obtained when
the PCR-generated L98H fragment was used for transforma-
tion.
Mutant analysis. Several different aspects of the A. fumigatus
transformants were analyzed: (i) antifungal drug susceptibility;
(ii) the DNA sequence, to verify the incorporation of sequence
changes; and (iii) cyp51A mRNA transcription levels.
In order to rule out the possibility of the integration of extra
copies of cyp51A in the transformation procedure, DNAs from
every transformant were digested with a restriction enzyme,
blotted, and hybridized (29) with a labeled fragment of cyp51A
(data not shown).
The cyp51A gene including the promoter area and the
cyp51B genes from all transformants were sequenced. All mu-
tants analyzed (nine) had incorporated the mutated cyp51A
allele corresponding to the fragment that was introduced (Ta-
ble 4). With the exception of the L98H mutation and/or du-
plication of the repeat in tandem, none of the transformants
had any other mutation in either cyp51A or cyp51B compared
to the sequence of wild-type strain CM237. The A. fumigatus
transformants’ susceptibilities to triazole drugs were deter-
mined as described above. All the transformants with both
cyp51A alterations (TR and L98H) exhibited susceptibility pro-
files similar to those of the clinical isolates (Table 4). However,
transformant CM237-TR7 had a slight but not significant in-
crease in azole drug MICs (P  0.01) that did not correspond
to an azole-resistant phenotype. Similarly, transformants ob-
tained with the akuBKU80 strain (containing either the TR or
the L98H modification independently) had a slight but not
significant increase in azole drug MICs (P  0.01) that did not
correspond to an azole-resistant phenotype (Table 4).
The levels of cyp51A mRNA expression in two transfor-
mants (strains CM237-TRL98H1 and CM237-TR7) in com-
parison with those in A. fumigatus azole-susceptible recipient
strain CM237 and two azole-resistant clinical strains (strains
CM2627 and CM3275) were analyzed. The relative increases in
the levels of cyp51A expression obtained in CM237-TRL98H1
were eightfold compared to the level of expression in the
wild-type strain, whereas the levels of cyp51A transcription in
CM237-TR7 were increased only fourfold compared to the
level of transcription in the wild type (Table 3). Also, the levels
of cyp51A mRNA expression in four mutants (strains akuBKU80-
TR2, akuBKU80-TR3, akuBKU80-L98H1, and akuBKU80-L98H3)
in comparison with that in their A. fumigatus recipient akuBKU80
strain were analyzed. The relative increases in the levels of cyp51A
expression obtained in strains akuBKU80-TR2 and akuBKU80-TR3
were between five- and eightfold those in the akuBKU80 parental
strain, whereas the levels of cyp51A transcription in strains
akuBKU80-L98H1 and akuBKU80-L98H3 were similar to that in
the parental akuBKU80 strain (Table 3).
DISCUSSION
In Candida spp., the majority of reports on azole drug re-
sistance are related to the increased efflux of azole drugs due
to the overexpression of efflux pumps of different types (4, 39,
42). In addition, a number of reports have identified polymor-
phisms in the erg11 gene (which is homologous to cyp51A)
from clinical Candida albicans isolates that are responsible for
and/or that are associated with fluconazole resistance (16, 26,
43). On the other hand, the resistance of filamentous fungi to
different demethylase inhibitors (DMIs) used for agricultural
purposes has mainly been correlated with one amino acid
change (Y136F) in the azole target, Cyp51 (11, 12, 53), or with
its overexpression (18, 23, 44, 46). In A. fumigatus, azole drug
resistance has been described for both laboratory mutants and
TABLE 4. Nucleotide and amino acids substitutions in A. fumigatus cyp51A and cyp51B genes and ranges of MICs of different antifungal
drugs for A. fumigatus mutant strains with the TR present in the cyp51A promoter and/or the Cyp51A amino acid substitution at L98H
Isolate or straina
cyp51A gene and promoterb cyp51B geneb MIC range (g/ml)c
Codon 54 Codon 98 Codon 220 TR Codon 35 Codon 394 AMB ITC VRC RVC PSC
CM237 (wild type) GGG CTC ATG (	) TCT CCT 0.25 0.25 0.5 0.5 0.12
M03/669 - CM2627 GGG 364CAC ATG () 105TCT 1285CCG 0.25 8.0 4.0–8.0 4.0–8.0 0.5
VC28–78 - CM3275 GGG 364CAC ATG () 105TCC 1285CCG 0.50 8.0 4.0 4.0 0.5
CM237-TRL98H1 GGG 364CAC ATG () TCT CCT 0.5 8.0 4.0 4.0–8.0 1.0
CM237-TRL98H3 GGG 364CAC ATG () TCT CCT 0.25 8.0 4.0 8.0 0.5–1.0
CM237-TRL98H4 GGG 364CAC ATG () TCT CCT 0.25 8.0 4.0 4.0 0.5–1.0
CM237-TRL98H5 GGG 364CAC ATG () TCT CCT 0.25 8.0 4.0 4.0–8.0 0.5–1.0
CM237-TR7 GGG CTC ATG () TCT CCT 0.50 0.5 1.0 1.0 0.25
akuBKU80 (recipient) GGG CTC ATG (	) TCT CCT 0.25 0.12–0.25 0.25–0.5 0.5 0.03–0.06
akuBKU80-TR2 GGG CTC ATG () TCT CCT 0.50 0.5 1.0 2.0 0.12
akuBKU80-TR3 GGG CTC ATG () TCT CCT 0.25–0.50 0.5 1.0 1.0–2.0 0.12
akuBKU80-L88H1 GGG 364CAC ATG (	) TCT CCT 0.25–0.50 0.5 1.0–2.0 1.0–2.0 0.12
akuBKU80-L88H3 GGG 364CAC ATG (	) TCT CCT 0.25–0.50 0.5 1.0–2.0 1.0–2.0 0.12
Amino acids (G54) (L98H) (M220) (S35S) (P394P)
a Mutant nomenclature: strains CM237-TRL98H1 to CM237-TRL98H5, gene replacement of the TRL98H fragment from strain CM2627 into azole-susceptible
strain CM237; strain CM237-TR7, gene replacement of the TR fragment from strain CM2627 into strain CM237; strains akuBKU80-L98H1 and akuBKU80-L98H3, gene
replacement of the L98H fragment from strain CM2627 into the akuBKU80 azole-susceptible strain; strains akuBKU80-TR2 and akuBKU80-TR3, gene replacement of
the TR fragment from strain CM2627 into strain akuBKU80.
b Nucleotides are numbered from the translation ATG start codon of cyp51A and cyp51B. The numbers indicate the position at which a base change occurs (in
boldface). TR (), presence of the 34-bp fragment duplication in tandem in the cyp51A promoter; TR (	), absence of the 34-bp fragment duplication in tandem in
the cyp51A promoter.
c AMB, amphotericin B; ITC, itraconazole; VRC, voriconazole; RVC, ravuconazole; PSC, posaconazole.
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clinical strains and has mainly been attributed to alterations in
the target enzyme (Cyp51A) (2, 15, 25, 28, 32). Even though
analysis of the A. fumigatus genome has shown the existence of
more than 40 ATP binding cassette transporter (ABC) ho-
mologs and more than 100 major facilitator transporter genes
(five times more than the number in yeast) (49), isolates that
overexpress efflux pumps as an azole resistance mechanism
have rarely been described. Nevertheless, there are a number
of reports of efflux pump overexpression related to azole re-
sistance in A. fumigatus, although these have been A. fumigatus
mutant strains generated in the laboratory and not clinical
isolates (9, 32). Only one clinical strain (strain AF72) has been
found to overexpress (by five times) the atrF gene (which
encodes an ABC transporter efflux pump), but only when it is
grown in the presence of itraconazole (46).
Up to now, decreases in the susceptibility of A. fumigatus to
itraconazole and posaconazole only (15, 25, 32) or to all azole
drugs (2, 29) have exclusively been linked to specific mutations
in cyp51A. The 14 A. fumigatus clinical strains described in this
study present a similar triazole cross-resistance phenotype but
have none of the known Cyp51A amino acid substitutions. A
new resistance mechanism that consisted of the presence of a
duplication of a TR in the cyp51A promoter and a L98H
substitution in the cyp51A-coding sequence was found in all
isolates. This fact strongly suggests that both alterations were
related to the azole-resistant phenotype. Nevertheless, we con-
ducted experiments to analyze each of the cyp51A modifica-
tions individually.
The results obtained with the mutants (strains CM237-TR7,
akuBKU80-TR2, and akuBKU80-TR3) suggest that the duplica-
tion of the 34-bp TR by itself seems to be insufficient for
reproduction of the resistant phenotype, even though there
was a four- to eightfold increase in the level of cyp51A expres-
sion which corresponded to a slight increase in azole MICs.
Previous reports have related azole resistance to the high level
of cyp51/erg11 expression in both yeast and filamentous fungi.
The mechanisms that have been associated with increased ex-
pression include gene or chromosome duplication and pro-
moter modification. The first mechanism, known in mammals
as gene amplification, was described in Candida glabrata (27)
and in an engineered laboratory strain of Aspergillus niger (50).
The latter mechanism has been seen in an A. nidulans triazole-
resistant strain obtained by amplification or overexpression of
the A. nidulans cyp51 gene expressed in a high-copy-number
plasmid (34). An increased level of cyp51 expression has been
suggested as a possible mechanism for sterol DMI resistance in
the plant pathogen Mycosphaerella graminicola (48). Similarly,
a DMI resistance mechanism has been described for another
plant pathogenic mold, Venturia inaequalis. The high level of
cyp51 expression was correlated with the presence of 553-bp
insertion located in the gene promoter (44). Also, just recently,
the analysis of 59 DMI-resistant isolates of Bumeriella jaapii
has shown 5- to 12-fold increased levels of cyp51 expression
related to various forms of a truncated non-long terminal di-
rect repeat, long interspersed nuclear retrotransposon element
(23). In Penicillium digitatum a mechanism similar to the one
that we describe has been reported for strains that have a
126-bp sequence tandemly repeated in the cyp51 promoter and
that is directly related to a pattern of resistance to different
DMIs. Nevertheless, the number of tandem repeats proved to
be essential for the production of a high level of DMI resis-
tance (18). Therefore, the results obtained in this study suggest
that the 34-bp sequence in the promoter region of cyp51A
might be a transcriptional enhancer and that its duplication is
responsible for the increased level of expression of cyp51A and
the higher A. fumigatus MICs for azole drugs. However, these
results also suggest that the TR duplication by itself is not
enough to confer the azole cross-resistant phenotype shown by
these strains. On the other hand, the introduction of the L98H
amino acid substitution at Cyp51A alone seems to be respon-
sible for only a slight increase in the A. fumigatus MICs for
azole drugs without influencing the cyp51A expression levels.
In the A. fumigatus Cyp51A protein, the leucine at position 98
is close to the first substrate recognition site (SRS1). This
residue is conserved throughout yeast and filamentous fungi
but not in plant or human Cyp51 proteins. An homology model
based on the X-ray crystal structure of Cyp51 from Mycobac-
terium tuberculosis was used to predict the specific Cyp51A
residues within A. fumigatus Cyp51A in combination with azole
drugs (54). However, the specific residue L98 has not been
implicated in any azole drug interactions with the protein (54).
The search for Cyp51A mutations at L98 in A. fumigatus
strains with intermediate MICs of azole drugs will help to
clarify whether this amino acid substitution is present in strains
isolated in the clinical setting and/or in environmental isolates
(these experiments are already under way in our laboratory).
Finally, the results obtained with the mutants incorporating
both cyp51A alterations (TR and L98H) confirmed that the
combination of both modifications is needed to reproduce the
azole-resistant phenotype shown by the clinical strains.
It is quite remarkable that since itraconazole-resistant A.
fumigatus strains were first described, A. fumigatus strains with
phenotypes of resistance to single or multiple azoles have
emerged in subsequent years. The recent isolation (2002 to
2006) of a number of A. fumigatus strains, all unrelated, with a
novel mechanism of azole resistance suggests that these molds
might be exposed to the selective pressure of azole compounds
either in the patient or in the environment. This aspect re-
quires further studies, especially in areas where 14--demeth-
ylase inhibitors are extensively used in agriculture.
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